Early initiation of SGLT2 inhibitors to retard diabetic kidney disease

Diabetic kidney disease is the leading cause of end-stage kidney disease in Singapore. For many years, the only classes of medication that have been shown to slow a decline in kidney function were angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs).

Optimisation of RAS blockade forms the core component of HALT-CKD (Holistic Approach in Lowering and Tracking Chronic Kidney Disease) programme. Recently, sodium–glucose cotransporter 2 (SGLT2) inhibitors have shown favourable effects on kidney outcomes in large clinical trials.

Early initiation of SGLT2 inhibitors should form an essential component of the diabetic kidney disease treatment algorithm. In this CME session, Dr Wong will share his experience in managing diabetic kidney disease using SGLT2 inhibitors.

Note: This is a CME-accredited event with priority given to Doctors and Allied Healthcare Professionals. StarMed reserves the right to refuse or cancel your registration at any time.